Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in people living with HIV-1
HIV-1에 감염된 사람들에서 BNT162b2 mRNA COVID-19 백신의 면역원성과 안전성
Article
[키워드] 95% CI
acute respiratory syndrome
acute respiratory syndrome coronavirus
Adverse
adverse event
adverse events
AIDS
anti-RBD
Antiretroviral therapy
appear
BNT162b2
BNT162b2 mRNA
BNT162b2 mRNA vaccine
CD4
CD4 cell
coronavirus
coronavirus disease
Coronavirus disease 2019
COVID-19 vaccine
disease
enrolled
event
events
fatigue
geometric
geometric mean
HCWs
headache
health-care
HIV-1
Human
Human immunodeficiency virus
IgG
immune
immunodeficiency
immunodeficiency virus
immunogenic
immunogenicity
injection
injection site
interquartile range
median
mRNA vaccine
neutralized
Neutralizing antibodies
neutralizing antibody
open
Pain
Patient
Pfizer-BioNTech
PLWH
positive
pseudo-virus
RBD
Receptor binding domain
reported
respiratory
Safe
SARS-CoV-2
second dose
sera
severe acute respiratory syndrome Coronavirus
severe acute respiratory syndrome coronavirus 2
suppressed
T-cell
vaccination
Vaccine
Viral
Viral load
were measured
[DOI] 10.1016/j.cmi.2021.07.031 PMC 바로가기 [Article Type] Article
[DOI] 10.1016/j.cmi.2021.07.031 PMC 바로가기 [Article Type] Article